Clinical Adverse Events In HIV-Infected Patients
All patients identified in the HIV registries will be included without any sampling
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Incidence rate of Malignancies
Median follow up of 3 years
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Investigational Review Board
A4001106
NCT01339416
October 2008
July 2013
Name | Location |
---|